WACKER BIOSOLUTIONS posted slightly higher sales in 2013. Sales rose 0.5 percent to € 158.4 million (2012: € 157.6 million), with the increase stemming from higher volumes. Sales growth was impeded by negative exchange-rate effects and lower prices. While business in both Asia and Europe as a whole expanded, sales in Germany and the Americas declined. Europe is the division’s largest sales region, with a share of more than 40 percent.

EBITDA for 2013 amounted to € 23.6 million, down slightly from the previous year (2012: € 24.5 million). EBITDA performance was dampened in particular by negative exchange-rate effects. The division’s EBITDA margin edged down to 14.9 percent (2012: 15.5 percent).

Investments Down from Prior-Year Level

Investments declined compared with the previous year, amounting to € 10.2 million (2012: € 19.3 million). Most of this sum went on constructing a new plant for polyvinyl acetate solid resins, which are used in the production of gumbase. With an annual capacity of 20,000 metric tons, the plant is being built at our Nanjing site in China. It will replace our existing production site at Wuxi. The new facility is scheduled to come on stream in 2014.

Pharmaceutical-Protein Business Reinforced by Acquisition

In November 2013, Wacker Biotech GmbH, a subsidiary of Wacker Chemie AG, signed a contract with BioNet Ventures GmbH to purchase a production site for the manufacture of therapeutic proteins. WACKER’s acquisition covers the assets of Scil Proteins Production at its site in Halle (Germany), including its patent portfolio. Scil Proteins has fermenters with a capacity of up to 1,500 liters. Acquiring this capacity is an important step in continuing to support customers after their drugs have passed the regulatory-approval stage and enter the commercial-supply phase. The acquisition was completed as per January 2, 2014 and the company will be included in WACKERs consolidated financial statements as of the first quarter of 2014.

As of December 31, 2013, the workforce at WACKER BIOSOLUTIONS rose to 371 (Dec. 31, 2012: 357).

Key Data: WACKER BIOSOLUTIONS